JP2015516985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516985A5 JP2015516985A5 JP2015509208A JP2015509208A JP2015516985A5 JP 2015516985 A5 JP2015516985 A5 JP 2015516985A5 JP 2015509208 A JP2015509208 A JP 2015509208A JP 2015509208 A JP2015509208 A JP 2015509208A JP 2015516985 A5 JP2015516985 A5 JP 2015516985A5
- Authority
- JP
- Japan
- Prior art keywords
- gcc
- antibody molecule
- cancer
- item
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 80
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 51
- 239000012472 biological sample Substances 0.000 claims description 35
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 27
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 26
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 206010039491 Sarcoma Diseases 0.000 claims description 18
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- 239000011541 reaction mixture Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
- 201000005202 lung cancer Diseases 0.000 claims description 13
- 238000002626 targeted therapy Methods 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 239000002254 cytotoxic agent Substances 0.000 claims description 10
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000009956 adenocarcinoma Diseases 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 238000001574 biopsy Methods 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 7
- 201000002314 small intestine cancer Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000003364 immunohistochemistry Methods 0.000 claims description 5
- 208000037841 lung tumor Diseases 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000011002 quantification Methods 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 claims description 2
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 claims description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 101710128063 Carbohydrate oxidase Proteins 0.000 claims description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims description 2
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 2
- 102100022624 Glucoamylase Human genes 0.000 claims description 2
- 108060001084 Luciferase Proteins 0.000 claims description 2
- 239000005089 Luciferase Substances 0.000 claims description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims description 2
- 108010014251 Muramidase Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 230000002055 immunohistochemical effect Effects 0.000 claims description 2
- 229960000274 lysozyme Drugs 0.000 claims description 2
- 239000004325 lysozyme Substances 0.000 claims description 2
- 235000010335 lysozyme Nutrition 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 239000012217 radiopharmaceutical Substances 0.000 claims description 2
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 2
- 208000014680 small intestine neoplasm Diseases 0.000 claims description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 claims description 2
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 6
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 6
- 108010044540 auristatin Proteins 0.000 description 6
- 108010093470 monomethyl auristatin E Proteins 0.000 description 6
- 108010059074 monomethylauristatin F Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639376P | 2012-04-27 | 2012-04-27 | |
| US61/639,376 | 2012-04-27 | ||
| PCT/US2013/038542 WO2013163633A1 (en) | 2012-04-27 | 2013-04-27 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017087084A Division JP6517267B2 (ja) | 2012-04-27 | 2017-04-26 | 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516985A JP2015516985A (ja) | 2015-06-18 |
| JP2015516985A5 true JP2015516985A5 (enExample) | 2016-06-16 |
| JP6472746B2 JP6472746B2 (ja) | 2019-02-20 |
Family
ID=49477498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509208A Active JP6472746B2 (ja) | 2012-04-27 | 2013-04-27 | 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 |
| JP2017087084A Active JP6517267B2 (ja) | 2012-04-27 | 2017-04-26 | 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017087084A Active JP6517267B2 (ja) | 2012-04-27 | 2017-04-26 | 抗ｇｃｃ抗体分子、およびｇｃｃ標的化療法への感受性を試験するためのその使用 |
Country Status (41)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2788457T3 (es) | 2009-10-23 | 2020-10-21 | Millennium Pharm Inc | Moléculas de anticuerpo anti-GCC y composiciones y métodos relacionados |
| CA2928043A1 (en) * | 2013-10-21 | 2015-04-30 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| ES2754282T3 (es) | 2014-02-14 | 2020-04-16 | Bioventures Llc | Aductos acetaminofén proteína y procedimientos de uso de los mismos |
| JP6785239B2 (ja) * | 2014-12-03 | 2020-11-18 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物 |
| CN109311994B (zh) | 2015-10-01 | 2022-06-07 | 药物研究及发展中心 | 抗足糖萼蛋白抗体及其使用方法 |
| EP3551745A4 (en) * | 2016-12-12 | 2020-07-15 | Xcella Biosciences, Inc. | SCREENING METHODS AND SYSTEMS USING MICROCAPILLARY NETWORKS |
| KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
| JP7197584B2 (ja) * | 2017-12-06 | 2022-12-27 | ベンタナ メディカル システムズ， インコーポレイテッド | デジタル病理学分析結果の格納および読み出し方法 |
| US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| CN112996492A (zh) * | 2018-09-05 | 2021-06-18 | 阿姆斯特丹大学 | Pde11或pde2抑制剂用于治疗帕金森氏疾病的用途 |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| TW202210513A (zh) * | 2020-06-02 | 2022-03-16 | 日商帝人製藥股份有限公司 | 抗ｉｇｆ－１受體人源化抗體 |
| WO2022127871A1 (en) * | 2020-12-17 | 2022-06-23 | Parasol Biotech Ltd. | Gucy2c binding molecules and uses thereof |
| CN116964100A (zh) * | 2021-04-07 | 2023-10-27 | 株式会社Lg化学 | Gucy2c结合多肽及其用途 |
| EP4594364A1 (en) * | 2022-09-28 | 2025-08-06 | Legend Biotech Ireland Limited | Antibody and chimeric antigen receptors targeting gcc and methods of use thereof |
| EP4611897A1 (en) | 2022-11-01 | 2025-09-10 | Heidelberg Pharma Research GmbH | Anti-gucy2c antibody and uses thereof |
| CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| WO2025061149A1 (zh) * | 2023-09-21 | 2025-03-27 | 南京传奇生物科技有限公司 | 抗gcc抗体、嵌合抗原受体及其用途 |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| CN120965861A (zh) * | 2025-10-22 | 2025-11-18 | 杭州博茵生物技术有限公司 | 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
| US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| CA2174928C (en) | 1993-10-26 | 2011-08-16 | Scott A. Waldman | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| ATE245163T1 (de) | 1996-05-03 | 2003-08-15 | Univ Jefferson | Impfstoff gegen metastasierenden kolorektalkrebs. |
| US6602659B1 (en) | 1996-05-03 | 2003-08-05 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| AU2001249504A1 (en) | 2000-03-27 | 2001-10-08 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| DK1377314T3 (da) | 2001-01-26 | 2011-12-12 | Inhibitex Inc | Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner |
| EP2944648B1 (en) | 2001-03-29 | 2019-11-13 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists for the treatment of organ inflammation |
| US7358054B2 (en) | 2001-04-13 | 2008-04-15 | Biogen Idec Ma Inc. | Antibodies to VLA-1 |
| DE60220719T2 (de) | 2001-12-28 | 2008-03-06 | Amgen Fremont Inc. | Antikörper gegen das muc18-antigen |
| WO2004024750A2 (en) | 2002-09-13 | 2004-03-25 | Dyax Corporation | Cd44-binding ligands |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US8206704B2 (en) | 2003-02-10 | 2012-06-26 | Thomas Jefferson University | Use of GCC ligands |
| JP4889493B2 (ja) | 2003-05-14 | 2012-03-07 | ドマンティス リミテッド | ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法 |
| US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
| EP1781339B1 (en) | 2004-06-25 | 2013-12-25 | Thomas Jefferson University | Guanylyl cyclase C ligands |
| BRPI0519596B1 (pt) | 2004-12-21 | 2022-01-18 | Astrazeneca Ab | Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CN101772513B (zh) | 2007-06-04 | 2013-11-13 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
| EP2188306B1 (en) * | 2007-08-10 | 2016-06-29 | Janssen Biotech, Inc. | Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| MX2010001395A (es) | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
| NZ628598A (en) * | 2007-11-30 | 2016-09-30 | Genentech Inc | Vegf polymorphisms and anti-angiogenesis therapy |
| US20110195415A1 (en) | 2008-05-13 | 2011-08-11 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
| CA2726913C (en) | 2008-06-04 | 2020-02-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2010065293A1 (en) * | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| US9364477B2 (en) * | 2009-02-12 | 2016-06-14 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| US20110306055A1 (en) | 2009-02-25 | 2011-12-15 | Diagnocure Inc. | Method for Detecting Metastasis of GI Cancer |
| EP2407786A4 (en) * | 2009-03-12 | 2013-01-02 | Univ Kinki | METHOD FOR PREDICTING THE EFFECTIVENESS OF CHEMOTHERAPY IN NON-SMALL CELL BRONCHIAL CARCINOMA |
| WO2010147684A1 (en) | 2009-06-15 | 2010-12-23 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
| WO2011066048A1 (en) | 2009-10-22 | 2011-06-03 | Thomas Jefferson University | Cell-based anti-cancer compositions and methods of making and using the same |
| ES2788457T3 (es) * | 2009-10-23 | 2020-10-21 | Millennium Pharm Inc | Moléculas de anticuerpo anti-GCC y composiciones y métodos relacionados |
| AU2011261161A1 (en) * | 2010-06-01 | 2013-01-10 | Ludwig Institute For Cancer Research Limited | Antibodies directed to the unprocessed receptor tyrosine kinase c-Met |
| CN103052404A (zh) * | 2010-08-13 | 2013-04-17 | 霍夫曼-拉罗奇有限公司 | 神经毡蛋白作为贝伐单抗联合疗法的生物标志物 |
| WO2013016662A1 (en) | 2011-07-28 | 2013-01-31 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| JP2016511257A (ja) * | 2013-02-28 | 2016-04-14 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与 |
-
2013
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko not_active Expired - Fee Related
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 CA CA2871614A patent/CA2871614C/en active Active
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en not_active Ceased
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/me unknown
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en not_active IP Right Cessation
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 SM SM20190536T patent/SMT201900536T1/it unknown
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/en not_active Ceased
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/en active Active
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
-
2014
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-24 PH PH12014502399A patent/PH12014502399B1/en unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja active Active
-
2019
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516985A5 (enExample) | ||
| JP6666905B2 (ja) | Ｐｄ−ｌ１抗体及びその使用 | |
| JP5770219B2 (ja) | Ｌｏｘおよびｌｏｘｌ２阻害剤ならびにこれらの使用 | |
| US9255142B2 (en) | Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof | |
| JP2023040115A (ja) | 葉酸受容体１の検出用の抗体及びアッセイ | |
| AU2021213421A1 (en) | Treatment of cancer | |
| JP2016503295A5 (enExample) | ||
| JP7022191B2 (ja) | 前立腺がんの分析のための組成物及び方法 | |
| JP2015533788A5 (enExample) | ||
| JP2018042573A5 (enExample) | ||
| JP2008529008A5 (enExample) | ||
| CA2871614A1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
| JP2015172045A5 (enExample) | ||
| JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
| JP2020510409A5 (enExample) | ||
| WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal | |
| BR112020010856A2 (pt) | Uso de conjugado de anticorpo anti-her2-fármaco no tratamento de carcinoma urotelial | |
| Kim et al. | Molecular imaging of colorectal tumors by targeting colon cancer secreted protein-2 (CCSP-2) | |
| JP2010535506A5 (enExample) | ||
| KR20110040624A (ko) | 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 | |
| KR101439856B1 (ko) | 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 | |
| WO2018135653A1 (ja) | 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出 | |
| CN114478780B (zh) | 识别磷脂酰肌醇蛋白聚糖3多个不同表位的抗体及其应用 | |
| JP6407990B2 (ja) | アウグリン免疫学的検定 | |
| CN115210256A (zh) | 用于前列腺癌诊断的新方法和化合物 |